Edition:
India

People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

4.30USD
8:32pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.30
Open
$4.30
Day's High
$4.32
Day's Low
$4.25
Volume
2,149
Avg. Vol
91,216
52-wk High
$7.44
52-wk Low
$1.90

Quartel, Adrian 

Mr. Adrian Quartel serves as Chief Medical Officer of the Company. Adrian brings over 20 years of global drug development and pharmaceutical experience, both in academia and industry. He was most recently global head of Medical Affairs at BioMarin, where he oversaw the launch of six products. Prior to BioMarin, Adrian held senior positions leading clinical development and as principal investigator for several studies at Chiltern. He also served in pharmacovigilance, clinical development, and medical affairs roles at Paraxel, Icon and, Astellas. Prior to joining the industry, Adrian worked as a clinical research fellow at UCLA Cedar Sinai and as a resident in cardio-thoracic surgery at Erasmus University Medical Center. Adrian received his medical degree from Erasmus University Medical School, Rotterdam, in the Netherlands, and his post graduate specialization in pharmaceutical medicine from the Faculty of Pharmaceutical Medicine in London. He is board certified by the General Medical Council (GMC) in pharmaceutical medicine in the United Kingdom.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Mahoney

264,876

Neil McFarlane

2,080,640

Christopher Prentiss

1,093,640

Adrian Quartel

--

Vijay Shreedhar

1,230,090

John MacPhee

67,705
As Of  31 Dec 2019